Literature DB >> 11350533

Parkinsonism and Parkinson's disease associated with long-term administration of sertraline.

M A Pina Latorre1, P J Modrego, F Rodilla, C Catalán, M Calvo.   

Abstract

Sertraline, a serotonin reuptake inhibitor, has been used to treat depression and has rarely been associated to Parkinsonism. The disease usually appears in old people a few days after sertraline administration and disappears very quickly after its withdrawal. We report a case of a woman, 81-year-old, who presented with hemiparkinsonism after long-term administration of sertraline at a dose of 100 mg/day. The symptoms disappeared 3 months after the withdrawal of the drug. However, without further administration of the drug for 14 months, the patient presented with Parkinson's disease, but responded well to levodopa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350533     DOI: 10.1046/j.1365-2710.2001.00307.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration.

Authors:  Tiffany W Chow; Mario F Mendez
Journal:  Am J Alzheimers Dis Other Demen       Date:  2002 Sep-Oct       Impact factor: 2.035

Review 2.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

3.  A Case of SSRI Induced Irreversible Parkinsonism.

Authors:  Siddharth Dixit; Shahbaj A Khan; Sudip Azad
Journal:  J Clin Diagn Res       Date:  2015-02-01

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

5.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.